Peptide Stacking with GLP-1s: What People Are Combining with Ozempic and Mounjaro

GLP-1 receptor agonists — semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) — are the most effective weight loss drugs ever approved. That's not in question. What's in question is what comes along with the weight loss. Three recurring problems drive the stacking trend: 1. Muscle loss. Up to 25% of weight lost on GLP-1 therapy can be lean mass. A 2026 Vanderbilt study (1,809 patients, JAMA Network Open) confirmed that both semaglutide and tirzepatide produce substantial fat loss with modest but real lean mass decreases. For patients who want body recomposition — less fat, more muscle definition — the GLP-1 alone gets them halfway there. 2. GI distress. Nausea, vomiting, and diarrhea are the most common GLP-1 side effects, especially during dose escalation. These are the number-one reason patients discontinue treatment. 3. Skin and tissue changes. Rapid weight loss of 15-25% body weight often leaves loose skin, reduced collagen density, and the "deflated" look that has become a recognized phenomenon in GLP-1 patients. Peptide stacking aims to address each of these with targeted compounds. The question is whether the rationale holds up — and whether the risks of adding unproven compounds to a proven therapy make sense.

The most common GLP-1 stack is a growth hormone secretagogue — typically CJC-1295/Ipamorelin or tesamorelin — to counteract lean mass loss. The rationale is straightforward: growth hormone promotes protein synthesis, supports muscle maintenance during caloric deficit, and has documented effects on body composition. GLP-1 drugs create a significant caloric deficit through appetite suppression; GH secretagogues theoretically protect the muscle that would otherwise be catabolized for energy. CJC-1295 (a GHRH analog) combined with Ipamorelin (a selective GH secretagogue) is the most prescribed combination. They have complementary kinetics — CJC-1295 provides sustained GH elevation while Ipamorelin triggers acute pulses. Clinicians who prescribe this stack typically report improved sleep quality and subjective recovery in patients, which may indirectly support lean mass preservation through better rest and training capacity. Tesamorelin has a unique advantage here: it's FDA-approved (for HIV-associated lipodystrophy) with documented effects on visceral fat. Phase III trials showed tesamorelin selectively reduced visceral adipose tissue by 15% over 26 weeks without altering subcutaneous fat or BMI. It also improved liver fat and hepatic function markers — relevant because GLP-1 patients often have concurrent NAFLD. As the only FDA-approved GH-releasing peptide, tesamorelin offers a level of safety data that CJC-1295/Ipamorelin cannot match. The honest limitation: no study has tested GH secretagogues specifically as adjuncts to GLP-1 therapy. The muscle-preservation logic is extrapolated from GH physiology, not from clinical trials of the combination. The magnitude of GH elevation from secretagogues is modest — far below replacement-dose GH — and whether it's enough to meaningfully offset GLP-1-induced muscle loss in well-nourished patients doing resistance training is genuinely unclear.

BPC-157 alongside GLP-1 therapy is arguably the most pharmacologically logical stack in the peptide world — and the one with the widest gap between rationale and human evidence. The case: BPC-157 (Body Protection Compound-157) is derived from human gastric juice and has over 30 preclinical studies showing gastroprotective effects. It accelerates healing of ulcers, reduces intestinal inflammation, and protects gastric mucosa across dozens of animal models. GLP-1 agonists cause GI distress as their primary side effect. Combining a potent gastroprotective peptide with a drug that hammers the GI tract is, on paper, an obvious move. Clinicians who prescribe this combination report that patients tolerate dose escalation better and experience less nausea. These are clinical observations, not controlled data — but they're consistent across enough practices to be taken seriously as a signal. The limitation is the same as always with BPC-157: zero published human clinical trials. The gastroprotective effects are from rat and mouse studies. We don't know the optimal human dose, the pharmacokinetics of oral vs. injectable BPC-157, or whether it interacts with GLP-1 receptor signaling in ways that could reduce efficacy. The preclinical case is among the strongest in the peptide space, but "strong preclinical" is not "proven in humans." Practical note: some patients use oral BPC-157 specifically for GI symptoms, reasoning that local delivery to the stomach and intestines is more relevant than systemic injection. This makes mechanistic sense but has no clinical data supporting it over injectable routes.

MOTS-c is the most intellectually interesting addition to a GLP-1 stack — and the one that could matter most if the science pans out. The biological logic: GLP-1 drugs shift metabolism aggressively toward fat oxidation. Fat burning is more mitochondrially demanding than glucose burning. When the pharmacological instruction to burn more fat arrives at mitochondria that were already running at capacity, the result is oxidative stress and metabolic inefficiency. MOTS-c — a mitochondrial-derived peptide that activates AMPK and PGC-1α — could theoretically expand mitochondrial capacity to keep pace with the increased oxidative demand. The preclinical data is compelling: MOTS-c doubled running capacity in mice, and endogenous levels increase 1.6-fold during exercise and 11.9-fold in skeletal muscle. It enhances insulin sensitivity through a pathway (AMPK) that is distinct from and complementary to GLP-1 signaling. Where GLP-1s reduce caloric intake and shift fuel preference, MOTS-c would ensure the cellular machinery can handle the shift. The limitation: no human supplementation trials exist, let alone combination studies with GLP-1s. This is an elegant theoretical stack built on preclinical foundations. Whether exogenous MOTS-c provides a meaningful signal above what exercise already delivers — especially in patients who are also training — is completely unknown. For patients on GLP-1 therapy who are doing the work (resistance training, adequate protein intake), the question is whether MOTS-c adds anything beyond what their training is already stimulating. The answer might be yes for sedentary or elderly patients with compromised mitochondrial function, but probably matters less for active individuals.

Rapid weight loss creates a skin problem. When patients lose 15-25% of their body weight over 12-18 months, the skin and underlying collagen matrix may not remodel fast enough to keep up. This has spawned a parallel aesthetic industry around post-GLP-1 skin tightening — and it's where GHK-Cu enters the stack. GHK-Cu has the strongest human evidence of any peptide in the aesthetics space. A 12-week topical study showed it improved collagen production in 70% of subjects, outperforming vitamin C cream (50%) and retinoic acid (40%). It modulates over 4,000 genes involved in collagen synthesis, antioxidant defense, and tissue remodeling. Natural GHK-Cu levels decline with age (from ~200 ng/mL at 20 to under 80 ng/mL by 60), providing a rationale for supplementation. The stacking logic for GLP-1 patients: support the collagen remodeling process during the window of rapid fat loss, potentially reducing the severity of loose skin. This is plausible — collagen synthesis is a rate-limiting factor in skin adaptation to volume loss — but no study has tested GHK-Cu specifically in the context of GLP-1-mediated weight loss. Most of the human data is topical GHK-Cu for facial skin. Injectable GHK-Cu for systemic collagen support is extrapolated from mechanism, not from trials. Patients adding this to a GLP-1 stack are making a reasonable bet based on solid topical data and biological plausibility, not on direct evidence for their use case.

The real-world stacking landscape is more conservative than the internet suggests. Based on clinical practice patterns reported at obesity medicine and functional medicine conferences in 2025-2026: The most common clinical stack is GLP-1 + CJC-1295/Ipamorelin. Clinicians add the GH secretagogue 1-2 months after establishing the patient on semaglutide or tirzepatide, once dose escalation is complete and GI symptoms have stabilized. The rationale is muscle preservation and improved sleep quality during the active weight loss phase. BPC-157 is the second most common addition, typically introduced during dose escalation to mitigate GI side effects. Some clinics use oral BPC-157 capsules; others prefer subcutaneous injection. GHK-Cu and MOTS-c are less commonly prescribed as GLP-1 adjuncts — they tend to appear in more aggressive functional medicine protocols rather than standard obesity medicine practice. Tesamorelin is used by clinicians who prefer FDA-approved options and is sometimes chosen over CJC-1295/Ipamorelin for patients with concurrent NAFLD or elevated liver enzymes, given its documented hepatic benefits. MK-677 (oral ibutamoren) occasionally appears as a GH-axis alternative that avoids injections, but its appetite-stimulating effects via the ghrelin receptor are counterproductive in patients whose GLP-1 therapy is suppressing appetite. Most clinicians avoid this combination for that reason.

Here's the uncomfortable truth about GLP-1 peptide stacking: no combination has been tested in a clinical trial. Every stack described in this article is assembled from individual compound data and pharmacological reasoning. The assumption is that effects are additive — that BPC-157's gastroprotection doesn't interfere with GLP-1 signaling, that GH secretagogues don't counteract the metabolic benefits of caloric restriction, that MOTS-c's AMPK activation complements rather than conflicts with GLP-1-driven metabolic changes. These assumptions may be correct. They may not be. Drug interactions are notoriously difficult to predict from mechanism alone. What has individual human data: • Semaglutide and tirzepatide — extensive Phase III and real-world data • Tesamorelin — FDA-approved, Phase III data for visceral fat and liver health • GHK-Cu — topical human trials for collagen and skin quality What has strong preclinical data only: • BPC-157 — 35+ animal studies for GI protection and tissue repair, one tiny human pilot • MOTS-c — compelling mouse exercise data, human observational correlations • TB-500 — animal models for tissue repair and inflammation What has minimal relevant data: • CJC-1295/Ipamorelin as GLP-1 adjuncts — no combination studies • Any multi-peptide stack — zero clinical evaluation of combinations The responsible framing is: these stacks are educated hypotheses, not evidence-based protocols. The pharmacological reasoning ranges from compelling (BPC-157 for GI protection) to speculative (MOTS-c for mitochondrial capacity). Patients should understand they are the experiment.

If you're on a GLP-1 and considering adding peptides, the most important interventions don't require a peptide at all: 1. Resistance training. This is the single most effective intervention for preserving lean mass during GLP-1 therapy. It works through mechanisms (mechanical tension, mTOR activation) that no peptide replicates. 2. Protein intake. Consuming 1.2-1.6 g/kg/day of protein is critical during GLP-1-mediated caloric restriction. This is harder when appetite is suppressed, which is why many clinicians prioritize protein-forward nutrition counseling before adding peptides. 3. Slow dose escalation. The standard dose escalation schedules exist for a reason — pushing too fast is the primary driver of GI side effects. If those foundations are in place and gaps remain, the peptide additions with the strongest rationale are: • BPC-157 for persistent GI issues during dose escalation — pharmacological logic is sound, preclinical evidence is strong, human data is lacking • Tesamorelin for patients with concurrent visceral fat and NAFLD concerns — FDA-approved, clinically validated for this specific application • CJC-1295/Ipamorelin for lean mass preservation if resistance training alone isn't sufficient — reasonable extrapolation from GH physiology, no combination data • Topical GHK-Cu for skin quality during rapid weight loss — human evidence for collagen support exists, though not in this specific context The peptides with the weakest case for routine GLP-1 stacking are MOTS-c (no human supplementation data), MK-677 (counterproductive appetite stimulation), and AOD-9604 (unclear added value when a GLP-1 is already driving fat loss). The trend toward GLP-1 peptide stacking reflects a real clinical need — these drugs have side effects and limitations that patients want to mitigate. The challenge is that most of the solutions being offered haven't been tested for the problem they're being applied to. Informed decision-making requires understanding that gap.